Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 12/31/2025

Management of Acute Kidney Injury in Rheumatic Heart Disease

Initial Assessment and Classification

  • The American Heart Association recommends classifying the severity of AKI using standardized staging criteria, including increases in serum creatinine of ≥0.3 mg/dL within 48 hours, or ≥1.5 times baseline, or urine output <0.5 mL/kg/h for 6-12 hours, to guide management and prognosis 1
  • The European Society of Cardiology suggests determining if AKI is primarily due to cardiorenal syndrome (type 1), which occurs in up to one-third of patients with acute heart failure, to inform treatment decisions 2
  • The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend assessing for risk factors that predispose to AKI in rheumatic heart disease, including hypotension, use of intra-aortic balloon pump, chronic heart failure, age >75 years, anemia, diabetes, and contrast exposure, to identify high-risk patients 1

Hemodynamic Optimization

  • The American College of Cardiology recommends improving cardiac output and renal perfusion through careful management of preload, afterload, and contractility, with a strength of evidence rated as high, to improve outcomes in patients with AKI and rheumatic heart disease 3, 4
  • The European Heart Journal suggests considering inotropic support in patients with low cardiac output to improve renal perfusion while maintaining adequate systemic blood pressure, with a moderate level of evidence, to support kidney function 4
  • The American Heart Association recommends optimizing pulmonary vasodilator therapy for patients with pulmonary hypertension and right ventricular failure, which is common in rheumatic heart disease, with a high level of evidence, to reduce morbidity and mortality 2

Fluid Management

  • The Kidney International journal suggests carefully assessing volume status, as both hypovolemia and hypervolemia can worsen kidney function in rheumatic heart disease, with a moderate level of evidence, to guide fluid management decisions 5
  • The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend monitoring for signs of fluid overload using clinical assessment and potentially newer techniques to detect volume status, with a high level of evidence, to prevent complications 5

Renal Replacement Therapy Considerations

  • The Kidney International journal recommends considering renal replacement therapy (RRT) for diuretic-resistant fluid overload, severe metabolic derangements, or progressive uremia, with a moderate level of evidence, to support patients with severe AKI 6
  • The European Renal Association suggests coordinating anticoagulation strategies carefully for patients requiring both extracorporeal life support and RRT, with a high level of evidence, to minimize bleeding risks 6

Medication Management

  • The Kidney International journal recommends implementing a nephrotoxic medication stewardship program that includes medication regimen review, assessment of pharmacokinetic/pharmacodynamic interactions, and dynamic prescription adjustments during transitions of care, with a high level of evidence, to reduce kidney injury 7
  • The Nature Reviews Nephrology journal suggests considering temporary discontinuation of nephrotoxic agents when the agent is determined to be the potential cause of AKI, a suitable and less nephrotoxic alternative is available, or the agent is considered non-essential, with a moderate level of evidence, to prevent further kidney damage 8

Special Considerations for Rheumatic Heart Disease

  • The American College of Cardiology recommends addressing valvular dysfunction, which is the hallmark of rheumatic heart disease and can contribute to AKI through hemodynamic derangements, with a high level of evidence, to improve outcomes 3
  • The European Society of Cardiology suggests considering tricuspid valve repair/replacement for severe tricuspid regurgitation contributing to volume overload and venous congestion, with a moderate level of evidence, to reduce morbidity and mortality 9
  • The American Heart Association recommends evaluating for pulmonary hypertension, which is common in rheumatic heart disease and can lead to right ventricular failure and subsequent kidney dysfunction, with a high level of evidence, to guide treatment decisions 2

Long-term Management and Follow-up

  • The Kidney International journal recommends monitoring for progression to chronic kidney disease, as post-AKI proteinuria is associated with future loss of kidney function, with a high level of evidence, to identify patients at risk 6
  • The American College of Cardiology suggests implementing shared decision-making and communication among caregivers, the patient, and family members, with a moderate level of evidence, to improve patient outcomes 6
  • The Circulation journal recommends avoiding nephrotoxins and limiting contrast exposure during follow-up imaging, with a high level of evidence, to prevent further kidney injury 9

Pitfalls and Caveats

  • The Kidney International journal suggests avoiding excessive fluid removal rates that may lead to intravascular volume depletion and worsen kidney function, with a moderate level of evidence, to prevent complications 7
  • The American College of Cardiology recommends being aware that patients with rheumatic heart disease often have multiple comorbidities that can complicate management of AKI, with a high level of evidence, to guide treatment decisions 3

Rosuvastatin Dosing and Management in Acute Kidney Injury

Renal‑Function–Based Dosing

AKI‑Stage–Specific Recommendations

Monitoring and Safety

Decision‑Making Algorithm (Key Steps)

REFERENCES